아미코젠

092040KOSDAQ

46.1 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40

News Sentiment19.6 / 25

Momentum5.0 / 20

Disclosure7.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Amicozen is an industrial biotech company specializing in developing enzymes for antibiotic production and health care materials using its proprietary gene evolution technology. Key products include N-acetylglucosamine, phytin, and collagen peptides, with expansion into endolysin enzyme business through collaboration with Lysando AG since 2020.

Number of Employees

228people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.75Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

-27.74Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

57.69Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼33.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼293.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -22.7% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 0Negative 1Average Sentiment Score 78.3

Negative
상장유지 요건 강화에 바이오 소재기업들도 퇴출 위기
아미코젠을 포함한 바이오 소재 기업들이 상장 유지 요건 미충족으로 퇴출 위기에 처해 있다.
Positive
아미코젠, 바이오소재 B2C 확장…'캐롭 피니톨 음료' 첫 선
아미코젠의 캐롭 유래 피니톨 음료 출시로 바이오소재 소비재 포트폴리오 확장 성공, 건강식품 시장 공략 강화.
Positive
"실험실 넘어 공장으로"…국산 바이오 소부장, 현장 도입 확대
아미코젠의 바이오 소부장 국산화 확대를 통한 현장 적용 확대가 바이오 공급망 안정화에 기여하며 긍정적 영향 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 1,019Won52-week high 4,22052-week low 953

1-month return3.0Point

1m -0.49% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

8 totalPositive 0Neutral 7Negative 1

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-03
Negative불성실공시법인지정예고 (공시번복 2건)2026-09-03
Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-08-31
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-08-31
Neutral[기재정정]반기보고서 (2026.06)2026-08-18